Pulmonary Embolism
Conditions
Brief summary
1. Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients. 2. Compare PERFORM score with the currently validated PESI in risk stratification of patients
Detailed description
Pulmonary embolism (PE) is a common and potentially lethal condition in the emergency department requiring early and accurate management. The short-term mortality rate of PE varies widely and ranges from less than 2% in many patients with non massive PE to more than 95% in patients who experience cardiorespiratory arrest. Although several prognostic models of acute PE are currently used, all of them have practical limitations. Of all clinical scores integrating PE severity and comorbidity, the Pulmonary Embolism Severity Index (PESI) and its simplified version,(sPESI) have been most extensively validated to date. However, current prognostic scores for pulmonary embolism (PE) are partly based on patients without PE confirmation via computed tomographic pulmonary angiography (CTPA), involving subjective parameters and complicated scoring methods \[8\]. Therefore, an objective, accurate, and simple prognostic model in CTPA-confirmed patients to predict the risk of 30-day mortality. help clinicians assess patients' risks and improve therapeutic decision-making that is called PERFORM score (pulmonary embolism risk score for mortality)
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
\- Patients above 18 years old with PE confirmed by CTPA are considered for inclusion in the study.
Exclusion criteria
* • Patients who have contraindications for CTPA eg. Renal impairment * Patients diagnosed and treated as PE without doing CTPA. * Patients who refuse to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess performance of PERFORM score in predicting outcome in CTPA confirmed patients. | from 11/2022 to 4/2024 |
Secondary
| Measure | Time frame |
|---|---|
| Compare PERFORM score with the currently validated PESI in risk stratification of patients. | from 11/2022 to 4/2024 |